MONEY

23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 15, 2024 - 16:00
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
Read More

Tags:

Previous Article

MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study...

Next Article

Air Canada reaches last-minute deal with pilots union, averting strike

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Taiwan set to hold rates steady on inflation worries: Reuters poll

Taiwan set to hold rates steady on inflation worries: R...

Tomas Kauer - Mode... Sep 16, 2024

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on

Acrivon Therapeutics Reports Positive Endometrial Cance...

Tomas Kauer - Mode... Sep 14, 2024

HP Imagine 2024: Innovating for the Future of Work

HP Imagine 2024: Innovating for the Future of Work

Tomas Kauer - Mode... Sep 13, 2024